News Category
Viromed Medical AG has completed a EUR 2 million capital increase, issuing 450,000 new shares at EUR 4.50 each, with proceeds earmarked for working ca...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its novel myelin-protective multiple sclerosis drug Lucid-MS into ...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant that supports cartilage regeneration, offering a potential alternative ...
American Fusion Inc. has moved its Texatron fusion program into active testing, achieving peak confinement pressures of 100,000 atmospheres, a key ste...
The 2026 Disruptive Growth & Life Sciences Conference, organized by Moody Capital Solutions, is set to provide a structured platform for under-covered...
SuzieQ Holdings Inc. will be featured at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, highlighting its role in build...
A new study confirms that treating select emergency room patients while seated, rather than waiting for a bed, can significantly reduce wait times and...
Helus Pharma completes enrollment in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder, with topline data expected in Q4 2026...
Helus Pharma's appointment of Michael Halstead as CEO, coupled with advancing Phase 3 trials, signals a strategic shift toward commercialization.
Ocumetics Technology Corp. has completed the second tranche of its private placement, raising $2.5 million to advance its first-in-human clinical tria...
Shareholders of VERAXA Biotech AG approved key corporate governance and financing proposals with over 99.94% support, providing flexibility for growth...
VERAXA Biotech announced that its bispecific antibody-drug conjugate program VXA-222 has reached a key technical milestone under its collaboration wit...
Gerresheimer has commenced operations at a new, sustainable plant in Zhenjiang Dagang, China, doubling its production capacity for glass primary packa...
Darwin AG has been renamed to Novogenia AG, aligning its corporate identity with its core operating brand to enhance visibility and recognition in per...
NanoViricides moves its oral gummies formulation of NV-387 toward a Phase II trial for the Bundibugyo ebolavirus outbreak in the DRC, addressing a cri...
Redwood AI's inclusion in the CSE25 Index signals its growth among the largest CSE-listed companies, potentially increasing investor interest and vali...
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trial for HLP003, a treatment for major depressive disorder, with top...
Quantum BioPharma is developing Lucid-MS, a first-in-class drug candidate that targets myelin repair, offering a potential breakthrough for the 2.9 mi...
The $410 billion nanomedicine market is gaining traction as companies like Oncotelic Therapeutics leverage advanced drug delivery platforms to enhance...
Quantum BioPharma's Lucid-MS, a first-in-class neuroprotective therapy for multiple sclerosis, is preparing for Phase 2 trials after positive Phase 1 ...
VERAXA Biotech announced new in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating tumor-restricted activation and dose-dependent k...
Redwood AI Corp. uses proprietary AI platforms to accelerate chemistry research and development, potentially transforming drug discovery, defense, and...
NanoViricides announced DRC regulatory approval to advance its Phase II Ebola trial for NV-387 Oral Gummies, the only oral Ebola treatment candidate u...
Helus Pharma's CMO will discuss the company's novel serotonergic agonists at a key industry conference, highlighting its Phase 3 depression treatment ...
Onco-Innovations has initiated process development and scale-up for its proprietary drug candidate ONC010, a milestone toward IND-enabling studies and...
Quantum BioPharma's LUCID-MS program shows promise in addressing the unmet need for myelin repair in multiple sclerosis, with phase 1 trials demonstra...
NeuroOne Medical Technologies will present at the Planet MicroCap Las Vegas 2026 Conference, providing commercialization updates and milestones for it...
GeoVax CEO David Dodd comments on recent pharmaceutical industry acquisitions, emphasizing the growing recognition of vaccine innovation and health se...
Quantum BioPharma Ltd. discussed its lead drug candidate Lucid-MS for multiple sclerosis and its commercial product unbuzzd on the BioMedWire Podcast,...
Helus Pharma announced its participation in the Jefferies Global Healthcare Conference, highlighting its progress in developing novel serotonergic ago...
TransCode Therapeutics has started a Phase 2a trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurre...
NanoViricides announces that its broad-spectrum antiviral NV-387 could be evaluated for the Bundibugyo Ebola outbreak, with its host-targeted mechanis...
SureNano Science Ltd. is advancing GEP-44, a GLP-1-based peptide for obesity and metabolic disorders, aiming to compete with blockbuster drugs like Oz...
Oncotelic Therapeutics integrates 28 million scientific abstracts into its PDAOAI platform, signaling a shift in drug discovery toward AI-driven infra...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn improved survival and reduced oxidative stress, hepatic copper, an...
Lantern Pharma receives FDA support for protocol amendments in its Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small c...
NanoViricides underscores the potential of its oral drug candidate NV-387 as a pandemic preparedness tool against the ongoing Bundibugyo Ebola outbrea...
Quantum BioPharma announced that its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached midpoint enrollmen...
LIXTE Biotechnology Holdings announced progress in its lead oncology candidate LB-100 and strategic expansion through its Liora Technologies subsidiar...
Dogwood Therapeutics announced Q1 2026 financial results, highlighting enrollment of 164 patients in its Halneuron Phase 2b CINP trial with data expec...
Innovations in blood-brain barrier penetration, such as Oncotelic’s intranasal nose-to-brain system, are poised to transform CNS therapeutics by enabl...
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provis...
Three deaths on the MV Hondius cruise ship due to hantavirus highlight the risks and need for awareness of this rare but dangerous infection.
NanoViricides announced FDA Orphan Drug Designation for its broad-spectrum antiviral NV-387 for measles, offering incentives and supporting developmen...
VolitionRx announces successful detection of nucleosomes in capillary blood from sepsis patients using a lateral flow finger-prick prototype, potentia...
Helus Pharma collaborates with TARA Mind and VETS to recruit veterans for its Phase 3 major depressive disorder trial, leveraging networks to enhance ...
Ventripoint Diagnostics announced that its strategic partner Lishman Global has submitted the VMS+ 4.0 system to China's NMPA for approval under an ex...
Formycon AG invites to a conference call on its FY2025 results on April 22, 2026, and announces participation in several international investor confer...
